RRF launches 'Ayusrem' a ayurveda remedy for swine flu
The Food & Drug Administration (FDA) in the Union Territory of Pondicherry has granted licence to Chennai-based Ramoni Research Foundation (RRF), an institute conducting research in Ayurveda medicines, to manufacture and market an Ayurvedic antiviral medication Ayusrem, which is a potential drug to prevent and treat H1N1.
The drug is made of extracts from anti-viral plants and antipyretic plants like Andrographis paniculata, Curcuma Longa and Vetiveria zizanioides. Extracts of Immunomodulant plants like Zingiber officinale and Piper nigrum have also been included. The Analgesic ingredients in the formulation are from Andrographis paniculata, Zingiber officinale and Cyperus rotundus.
The foundation hopes that the permission by the US FDA will reap results in a way that it will help RRF to penetrate into the huge Indian Ayurvedic market and the growing global market of Ayurvedic products when viral diseases are spreading alarmingly and taking lives across the world. RRF's Ayusrem is the outcome of a joint venture with the Herbal Science Research Centre of Madras University.
After the invention of Ayusrem, Ramoni Research Foundation has bagged three Awards of Excellence. 'National Citizen Excellence Award' from 'Intellectual People and Economic Growth Association', New Delhi for Outstanding Contribution, 'International Achievers Award' for invention of 'Ayusrem' by International Achievers Forum, Thailand, and 'Bharath Gaurav Award' from 'India International Friendship Society' for meritorious services.
The foundation, RRF has signed an agreement with Pondicherry based Dr Milton's Laboratories to manufacture the drug and inked another contract with Chennai-based Berjayaa Marketing Private Ltd for domestic marketing. They have also signed certain pacts with Leonex Systems of Malaysia to market the Ayurvedic antiviral remedy.
Venus Remedies launches India's First Infusion FDC antibiotic to fight GI infections
Venus Remedies Ltd, a fast-growing pharmaceutical company in the country, has launched MEBATIC, a unique antibiotic combination in infusion form to cure severe gastro intestinal (GI) infections.
Launched with unique and distinct combination of Floroquinolone & Nitroimidazole, MEBATIC has been identified as the best solution for treating micro-organisms like anaerobes, aerobes and protozoa that cause diseases like watery diarrhea, dysentery, enteritis, traveler's diarrhea, and acute food poisoning.
MEBATIC INFUSION has shown 20 to 25 per cent improved efficacy over the existing therapies. The drug has also been developed with a 'Chemical Vector' that promotes faster recovery and ensures deeper penetration of antibiotic at the site of infection.
Anaerobes being difficult to detect and treat are a major cause of concern for medical fraternity practicing in India and across the globe. "More effective and innovative therapies like MEBATIC are needed as the micro-organisms are becoming increasingly resistant to the existing antibiotics like Metronidazole. Due to the increased drug resistance mortality associated with anaerobes in India has gone up to 24-31%, which is indeed a cause of concern,"said Dr. Manu Chaudhary Director and head Venus Medicine Research Center (VMRC), the R&D arm of Venus Remedies.
Indian Pharmaceutical market was USD 11.50 billion in 2008-09 and out of this the Gastrointestinal drugs segment contributes to 10.70% of total market making the GI market size of approx. 1.2305 billion USD.
MEBATIC is also the best choice available for pre and post surgical procedures, pelvic infections, urinary tract infections, uro-genital tract infections, typhoid & prevention of ICU infections, caused due to the presence of Anaerobes in the human body.
The drug has been approved by the Drugs Controller General of India (DCGI) after successful phase III comparative clinical trials conducted by VMRC.
|
|
